Genmab — April 2014
-
mens vi venter på FDA er her en udmærket artikel, der diskutere udviklingen i biotek og om der findes en bobbel -
http://www.marketwatch.com/story/is-biotech-caught-in-a-bubble-and-is-it-popping-2014-04-08 -
er det bare min inbox, der ikke fungerer? Jeg mangler stadig en meddelelse fra fda.... Kunne være forrygende om Jan kunne smide den på bordet her på GF dagen...
-
har i set at Takeda får tæsk med over -10% pga en retssag i US? skal betale 6 mia usd i bøde i Louisiana
-
well - jeg mener at fredag i næste uge for det meste er en helligdag i US og Børsen er lukket. Mon ikke fda gerne vil have unfinished business af bordet inden Påsken?
-
faktisk er fredag en federal holiday - så vi må have 7 børsdage tilbage....
-
Det er forresten en interessant indledning, der er til den nye EGFR cMET: NSCLC with activating mutations in the EGFR gene are associated with high response rates to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, but invariably acquired resistance emerges over time. A primary cause of resistance is the emergence of secondary mutations in EGFR which neutralize the effectiveness of TKIs.
-
Altså i forhold til konkurrencen fra TK. http://ir.genmab.com/downloads.cfm
-
det må man sige - og man kan jo også tolke lidt på den sidste sætning: The preclinical data support the clinical development of JNJ-61186372 in patients with lung cancer and other malignancies associated with aberrant EGFR and cMET signaling
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind